Key facts
- Notable investors include Fuzhe Capital, Zhejiang State-Owned Capital Operation, BrightGene Bio-Medical Technology Company, China Cinda Asset Management.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Borui Biopharmaceutical Taixing
- ·The full record, as it builds
Funding rounds
No funding rounds for Borui Biopharmaceutical Taixing are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Borui Biopharmaceutical Taixing
Manufacturer of pharmaceutical raw materials and intermediates designed for therapeutic and industrial applications. The company offers large-scale production of active pharmaceutical ingredients, chemical intermediates, and biologically derived compounds and development capabilities, enabling global pharmaceutical enterprises and healthcare markets to secure reliable supply chains, maintain consistent quality standards, accelerate product development, and strengthen competitiveness.
- Sector
- Healthcare
- HQ
- Taixing, China
- Founded
- 2007
- Ownership
- Privately Held (backing)
Borui Biopharmaceutical Taixing doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Borui Biopharmaceutical Taixing shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Borui Biopharmaceutical Taixing in its N-PORT filings yet. We sweep new filings monthly.